GlassScriptPhysician profile
Arthur S Hernandez
NPI 1568428589
$4,003.79
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $546 · 2021: $861 · 2022: $872 · 2023: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $127.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Titan Pharmaceuticals, INC. | $820.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $531.24 | 2019-2023 | Relistor |
| Abbvie INC. | $414.36 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $366.59 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $206.22 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $204.78 | 2019-2023 | Ajovy |
| Allergan, INC. | $152.54 | 2020 | |
| Amgen INC. | $142.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $120.44 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $107.33 | 2021 | |
| Abbott Laboratories | $99.04 | 2019-2021 | |
| Pfizer INC. | $93.16 | 2019-2023 | |
| Daiichi Sankyo INC. | $77.98 | 2019 | |
| Scilex Pharmaceuticals INC. | $72.78 | 2019-2022 | |
| Lilly USA, LLC | $68.58 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $66.69 | 2020 | |
| Global Blood Therapeutics, INC. | $51.92 | 2021-2022 | |
| Grt US Holding, INC. | $39.73 | 2021 | |
| Biodelivery Sciences International, INC. | $35.43 | 2020-2021 | |
| Redhill Biopharma INC. | $35.10 | 2020-2021 | |
| Lundbeck LLC | $31.23 | 2021-2022 | |
| Forte Bio-Pharma LLC | $30.48 | 2021 | |
| Shionogi INC | $29.01 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $27.93 | 2022 | |
| Indivior INC. | $27.11 | 2023 | Sublocade |
| Medtronic USA, INC. | $26.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.77 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.96 | 2022 | |
| Depuy Synthes Sales INC. | $17.69 | 2021 | |
| Mdd US Operations, LLC | $15.76 | 2020 | |
| Merck Sharp & Dohme LLC | $13.35 | 2022 | |
| Currax Pharmaceuticals LLC | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.